Clinical Trial Update: A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older [Phase 4]

View source ↗

Summary

This Phase 4 trial evaluated the safety and immunogenicity of the ADACEL vaccine in adults 65 years and older, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• ADACEL® vaccine (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap))

Snippet

Sponsor: Sanofi | Conditions: Pertussis, Tetanus | Phase 4 | Status: COMPLETED | Results posted: 2012-10-19